Background: Vitamin K antagonists (VKA) remain the mainstay of anticoagulation therapy, which requires monitoring of international normalised ratio (INR). Quality of oral anticoagulation, clinical benefits and the risk related to VKA application are determined by time in the therapeutic range (TTR). Aim: The aim of this study was to assess the therapeutic quality of oral anticoagulation and to determine factors that affect the incidence of INR outside the recommended range in primary care patients undergoing long-term VKAs therapy in Poland. Methods: A multi-centre cross-sectional analysis was carried out in fifteen general practices from three voivodeships of Poland. At the planned time, all patients' INRs measured closest to the designated date were assessed in terms of being in therapeutic range. Time in the therapeutic range (TTR) was determined as the Percent of Visits with INR in Range on Given Date. Results: Overall 430 patients at the average age of 70.3 ± 12.7 year (222 males at the average age of 72 ± 12.8, and 208 females at the average age of 68.5 ± 12.4) were included in the study. Average patient age in the groups with INR below, within, and above range, was 67.3 ± 13.4, 72 ± 12 and 70.5 ± 13 (p = 0.001), respectively. TTR for all the participants was equal to 55%. Statistically significant factors associated with an INR out of the therapeutic range were: age under 60 years compared to older persons (p = 0.003), more or less frequent INR control compared to the recommended intervals of 4 to 8 weeks (p < 0.001), and the type of applied VKA — acenocoumarol compared to warfarin (p < 0.001). Logarithmic regression analysis showed that the use of acenocoumarol, instead of warfarin, increased the chances of INR being below therapeutic range (odds ratio [OR] 3.19; 95% confidence interval [Cl] 1.65–6.16); while male gender increased probability of INR being above the range (OR 2.01; 95% Cl 1.12– 3.59). Conclusions: TTR in primary care patients on VKA therapy was 55%. Better quality of oral anticoagulation with VKA could be achieved by using warfarin instead of acenocoumarol, proper INR monitoring in the recommended intervals of 4 to 8 weeks, and tighter INR control in younger and male patients. Background: Vitamin K antagonists (VKA) remain the mainstay of anticoagulation therapy, which requires monitoring of international normalised ratio (INR). Quality of oral anticoagulation, clinical benefits and the risk related to VKA application are determined by time in the therapeutic range (TTR). Aim: The aim of this study was to assess the therapeutic quality of oral anticoagulation and to determine factors that affect the incidence of INR outside the recommended range in primary care patients undergoing long-term VKAs therapy in Poland. Methods: A multi-centre cross-sectional analysis was carried out in fifteen general practices from three voivodeships of Poland. At the planned time, all patients' INRs measured closest to the designated date were assessed in terms of being in therapeutic range. Time in the therapeutic range (TTR) was determined as the Percent of Visits with INR in Range on Given Date. Results: Overall 430 patients at the average age of 70.3 ± 12.7 year (222 males at the average age of 72 ± 12.8, and 208 females at the average age of 68.5 ± 12.4) were included in the study. Average patient age in the groups with INR below, within, and above range, was 67.3 ± 13.4, 72 ± 12 and 70.5 ± 13 (p = 0.001), respectively. TTR for all the participants was equal to 55%. Statistically significant factors associated with an INR out of the therapeutic range were: age under 60 years compared to older persons (p = 0.003), more or less frequent INR control compared to the recommended intervals of 4 to 8 weeks (p < 0.001), and the type of applied VKA — acenocoumarol compared to warfarin (p < 0.001). Logarithmic regression analysis showed that the use of acenocoumarol, instead of warfarin, increased the chances of INR being below therapeutic range (odds ratio [OR] 3.19; 95% confidence interval [Cl] 1.65–6.16); while male gender increased probability of INR being above the range (OR 2.01; 95% Cl 1.12– 3.59). Conclusions: TTR in primary care patients on VKA therapy was 55%. Better quality of oral anticoagulation with VKA could be achieved by using warfarin instead of acenocoumarol, proper INR monitoring in the recommended intervals of 4 to 8 weeks, and tighter INR control in younger and male patients.